Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis

OBJECTIVE: We aimed to assess risk factors for the development of severe infection in patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV) receiving rituximab. METHODS: 192 patients with AAV were identified. Univariate and multivariate analyses were performed to identify risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Kronbichler, Andreas, Kerschbaum, Julia, Gopaluni, Seerapani, Tieu, Joanna, Alberici, Federico, Jones, Rachel Bronwen, Smith, Rona M, Jayne, David R W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161662/
https://www.ncbi.nlm.nih.gov/pubmed/29950327
http://dx.doi.org/10.1136/annrheumdis-2017-212861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161662/
https://www.ncbi.nlm.nih.gov/pubmed/29950327
http://dx.doi.org/10.1136/annrheumdis-2017-212861

Ejemplares similares